Early series in living donor liver transplantation (LDLT) in adults demonstrated a lower safe limit of graft volume standard liver volume ratio 25%-45%. A subsequent worldwide large LDLT series proposed a 0.8 graft recipient weight ratio (GRWR) to define small-for-size graft (SFSG) in adult LDLT. Thereafter, researchers identified innate and inevitable factors including changes in liver volume during imaging studies and graft shrinkage due to perfusion solution. Although the definition of small-for-size syndrome (SFSS) advocated in the 2000s was mainly based on prolonged cholestasis and ascites output, the term SFSS was inadequate to describe clinical manifestations possibly caused by multiple factors. Thus, the term "early allograft dysfunction (EAD)," characterized by total bilirubin ＞10 mg/dL or coagulopathy with international normalized ratio ＞1.6 on day 7, has become prevalent to describe graft dysfunction including SFSS after LDLT. Although various efforts have been made to overcome EAD in LDLT, graft selection to maintain an expected GRWR ＞0.8 and full venous drainage, as well as inflow modulation using splenic artery ligation, have become standard in recent LDLT.
INTRODUCTION
Living donor liver transplantation (LDLT) was first introduced for pediatric patients in Brazil in 1989 [1] , the positive outcomes of which resulted in the gradual recognition of LDLT as a treatment of choice for pediatric patients with end-stage liver diseases [2] . In 1993, Kawasaki et al. [3] reported in their pediatric LDLT series that a graft volume standard liver volume ratio (GV/SLV) of 46% was within the safe limit. They were the first to use the term "small-for-size (SFS)" graft to describe grafts with GV/SLV ＜1.0. In 1994, the same Shinshu group [4] performed the first LDLT in adults using a left lobe graft with a GV/SLV of 45% in a small adult female recipient. In 1996, a Hong Kong group [5] reported successful adult LDLT using a left lobe graft with 25% of the ideal liver size in a patient with acute liver failure, thus demonstrating that an SLV of 25% was within the limit for successful LDLT.
However, Emond et al. [6] reviewed pediatric LDLTs using lateral segment grafts (n=23) and adult LDLT using left lobe grafts (n=2), reporting delayed functional recoveries in five recipients receiving a SFS graft defined as ＜50% of the expected total liver size and non-func- tion as a case with 23% of the expected total liver size.
They reported that an SFS graft ＜50% of the expected total liver size showed characteristic pathological presentations including ischemia, cholestasis, and regeneration after LDLT. Under such circumstances, the Hong Kong group [7] in turn reported that right lobe grafts with the middle hepatic vein should be used in adult LDLT to prevent SFS-related graft dysfunction, demonstrating the safety of removing the extended right lobe in donors.
DEFINING SFSG
In 1997, the Kyoto group also showed negative outcomes of left lobe grafts with graft recipient weight ratio (GRWR) ＜1.0, especially in older donors [8] and revised their strategy in 2000 to use mainly right lobe grafts without the middle hepatic vein in adult LDLT with GRWR ≥0.8 [9] . Recently, the group decreased the lower limit of graft weight to a GRWR of 0.7 for under extensive inflow modulation using splenectomy [10] . The Kyushu group initially started the LDT program with a lower limit of GV/SLV of 30% with successful outcomes in the initial series [11] . However, the initial 50 cases performed with this strategy resulted in prolonged cholestasis and ascites output in 20% of cases. Therefore, to decrease the incidence of graft dysfunction and maximize the success rate, the Kyushu group instead used more right lobe grafts, not less than 35% of the lower limit of GV/SLV, corresponding to a GRWR of 0.7% under aggressive graft inflow modulation [12] . In 2001, the Tokyo group reported prolonged cholestasis and elongation of prothrombin time for GV/SLV ＜40%, resulting in poor graft survival (80%); thus, a GV/SLV of 40% has been used as the lower limit for graft selection since [13] . A literature review showed that the major LDLT transplant centers in Eastern and Western countries apply a GRWR of 0.8 or GV/SLV of 40% of the expected graft size as the safe limit for successful LDLT without inflow modulation [14] [15] [16] [17] [18] . Currently, SFSG can be defined as a GRWR of 0.8 or GV/SLV of 40%, although small-for-size syndrome (SFSS) after an LDLT graft could be attributed to multiple factors including not only graft size but also donor age, graft steatosis, recipient condition, and portal hypertension [19] [20] [21] [22] [23] .
DIFFERENCES IN EXPECTED AND ACTUAL GRAFT VOLUMES
When debating the graft volume (GV), we should consider the differences between expected and actual GVs.
Urata et al. [24] showed that the conversion ratio for liver weight (g) and liver volume (cm Fig. 1A and B ). Pathological findings in primary graft dysfunction can be distinguished from cholestatic lobular hepatitis C by pan-lobular hepatocyte ballooning (Fig. 1C ) and acute rejection with mixed cellular infiltrations around the periportal area (Fig. 1D ).
In the meantime, the concept of early allograft dysfunction (EAD) characterized by high early aminotransferase levels, persistent cholestasis, and coagulopathy in the first week after LT in the use of extended-criteria donors for deceased donor liver transplantation has been accepted in Western countries [36] [37] [38] . Olthoff et al. [39] proposed a definition of EAD in LDLT as the presence of jaundice with bilirubin ＞10 mg/dL or coagulopathy with an INR ＞1.6 on day 7 without technical complications. The following A2ALL study [40] showed that EAD, with a five-fold risk of short-term graft loss, was associated with a left lobe graft, smaller graft weight, higher preoperative bilir- 
HOW TO OVERCOME EAD AFTER LDLT
The basic concept of EAD including SFSS is represented by the absence of technical complications, and inflow and outflow issues as previously described [42] [43] [44] .
The major donor and recipient factors associated with EAD after DLLT include GRWR ＜0.8, donor age ＞45 years, MELD score ＞20, recipient with sarcopenia and unable to walk independently, posttransplant portal pressure ＞15 mmHg, and post-LDLT complications including sepsis [17] [18] [19] [20] [30] [31] [32] [33] [34] [35] [42] [43] [44] . Because management of recipients with end-stage liver disease is difficult, donor and graft selection with inflow modulation to control portal pressure are the only options to overcome EAD.
Among inflow modulation methods, splenic artery ligation is widely recognized as the safest intervention with optimal outcomes [34, [45] [46] [47] . The benefit of splenic artery ligation is attributed to increased hepatic arterial inflow due to obstruction of the splenic artery and decreased portal inflow via splenic outflow. The possible challenge in splenic artery ligation is the potential for bleeding and pancreas injury due to a deeply located splenic artery beneath the pancreas. The Kyushu group has performed simultaneous splenectomy during LDLT with the use of vessel sealing devices and endo-stapling devices to perform tie-less and blood-less splenectomy, with more potent decompression of portal inflow than that of splenic artery ligation [48] [49] [50] . The rationale for splenectomy is based on the fact that spleen is a major supplier of vasoconstrictive molecules, including endothelin, to the liver; thus, splenectomy results in hepatic vasodilatation [51, 52] . Ikegami et al. [50] usually performed splenic artery ligation before splenectomy for easier and safer handling of enlarged spleens in end-stage liver disease. However, splenectomy is not globally recognized as a standard inflow modulation procedure in LDLT, except for the Kyushu and Kyoto groups, due to bleeding complications, portal and splenic venous thrombus, and post-splenectomy sepsis. Recently, the Asan group reported innovative splenic devascularization in LDLT, with sufficient portal decompression and fewer complications compared to those for splenectomy [53] .
The creation of portosystemic shunts for portal decompression was first reported in the early to middle 2000s, with optimal outcomes in LDLT using extremely small grafts [54] [55] [56] . However, because of unstable portal inflow due to liver regeneration in LDLT and portal steal phenomena leading to graft mortality, no Japanese institute has recently performed this procedure [44] . We experienced a case requiring an extra-small graft with expected and actual GV/SLV of 36% and 23%, respectively, from a 20-year-old donor into a patient with hepatocellular carcinoma, in which an end-to-side portocaval shut after splenectomy was created to modulate excessive portal inflow to the small graft [57] . The graft showed hepatofugal portal flow 4 days after surgery, followed by immediate re-laparotomy for shunt ligation, resulting in a good postoperative course. We should have recognized that this young and soft graft had an expected GV/SLV of 36% to accommodate sufficient portal flow and that the GV/SLV of 23% was a temporary presentation due to dehydration [26] [27] [28] [29] .
The generally recommended strategies for graft se- 
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